% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Tigu:306669,
      author       = {A.-B. Tigu and M. Nistor and D. Gulei and C.-S.
                      Constantinescu and D. Kegyes and D. Cenariu and X. Muresan
                      and R. Munteanu and R. Feder and C. Jitaru and A. Bancos and
                      M. Santa and R. Tomai and M. Damian and A. Ivancuta and I.
                      Rus and A. Bojan and M. Zdrenghea and A.-D. Buzoianu and A.
                      Tanase and H. Einsele and S. Kobold$^*$ and C. Tomuleasa},
      title        = {{CAR}ing about autoimmune disorders. {U}se of chimeric
                      antigen receptor engineered {T}-cells in autoimmune
                      diseases.},
      journal      = {Blood reviews},
      volume       = {nn},
      issn         = {0268-960X},
      address      = {Burlington, Mass.},
      publisher    = {Harcourt},
      reportid     = {DKFZ-2025-02662},
      pages        = {nn},
      year         = {2025},
      note         = {epub},
      abstract     = {Chimeric Antigen Receptor (CAR) T cell therapy, initially
                      developed for hematologic malignancies, has recently emerged
                      as a promising modality for treating autoimmune diseases.
                      This review explores the evolving role of CAR T cells in
                      reprogramming immune tolerance and achieving durable
                      remission in autoimmune disorders. By engineering T cells to
                      target pathogenic B cells or autoreactive T cells, CAR T
                      therapy offers a targeted and potentially curative approach
                      for diseases such as systemic lupus erythematosus, multiple
                      sclerosis, and type 1 diabetes. Early clinical trials and
                      preclinical models have demonstrated the feasibility,
                      safety, and efficacy of CD19-targeted CAR T cells in
                      depleting autoreactive B cells and restoring immune
                      homeostasis. Furthermore, next-generation CAR
                      designs-including regulatory T cell-based CARs and
                      antigen-specific constructs-highlight the growing precision
                      and versatility of this platform. Despite these advances,
                      challenges remain, including potential toxicity, antigen
                      escape, and the need for long-term immune monitoring. This
                      review summarizes current findings, delineates mechanistic
                      insights, and discusses future directions for optimizing CAR
                      T cell therapies in the context of autoimmunity.},
      subtyp        = {Review Article},
      keywords     = {Autoimmune diseases (Other) / CAR T cells (Other) /
                      Emerging therapies (Other)},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41318274},
      doi          = {10.1016/j.blre.2025.101354},
      url          = {https://inrepo02.dkfz.de/record/306669},
}